SYK Q3 2026 Earnings Analysis
Q3 organic sales 7.7% offset by hip/knee slowdown to ~2.5%; revised FY guidance to 6.5%-7%. Completed ZuriMED deal, CMR Versius partnership. Margins expanded despite sales pressure.
Key Metrics
Wichtigste Erkenntnisse
- Organic sales grew 7.7% Q3 but hip/knee market slowed to ~2.5%; revised full-year organic guidance to 6.5%-7%.
- Completed ZuriMED acquisition and strategic CMR Surgical investment for Versius soft tissue robot commercialization.
- Gross margin 65.4% (+40 bps), operating margin 26.2% (+60 bps); YTD cash from operations $3.3B, up 14%.
Anhören auf
Verfügbar in
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Stryker's third quarter 2026 results. There's a lot to unpack here—an orthopaedics slowdown, a big robotics announcement, and a CEO transition all in one call. But before we get into it, the standard note: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Right, and this one's actually a pretty meaty transcript, Alex. It's Kevin Lobo's last earnings call as CEO—57 quarters, which is a wild number—before he hands the reins to Spencer Stiles. So there's a bit of a "passing the torch" energy, but also some real business headwinds to address.
Let's start with the numbers. Stryker posted organic sales growth of 7.7% for the quarter. Adjusted EPS came in at $3.52, up about 10% year-over-year. On the surface, that sounds pretty solid.
It does, but the devil's in the segment details. MedSurg and Neurotechnology grew 9.1%—that's the strong part of the story. Endoscopy was up double digits in the U.S., Medical grew 10%, Vascular grew 13%. But Orthopaedics—their bread-and-butter joint replacement business—only grew 5.9%, and within that, U.S. Knees were up just 1.3% and U.S. Hips actually declined slightly.
And that's really the headline story here, right? Management flagged a genuine market slowdown in U.S. hip and knee procedures.
Exactly. Kevin Lobo was pretty candid about it. He pointed to patient affordability issues—higher deductibles, higher premiums—plus an uptick in insurance pre-authorization denials that's delaying patients from getting procedures done. He estimated the overall hip-and-knee market is now growing around 2.5%, which is a notable step down from the 5-6% range we've seen in recent years.
And it wasn't just market softness—Stryker also admitted they're not winning share at their historical pace.
Right, and they were refreshingly honest about why. 2026 has been a messy year operationally. There was the cyber incident back in Q1, and then in July they completed their final SAP system implementation within Orthopaedics. Management said that actually delayed their visibility into real-time market conditions—they didn't fully grasp the slowdown until September, during an investor conference.
That's a pretty candid admission—basically saying "we were flying partially blind on our own numbers."
It is. And it ties into why new products like Mako RPS and Triathlon Gold haven't scaled as fast as hoped—not a product problem, they said, but a commercial execution and distraction problem. The silver lining: they're bringing a power hip impaction tool to market next year, which fills a real gap in their hip portfolio and could help with competitive conversions.
Let's talk strategy, because there were two notable moves this quarter. First, they closed the acquisition of ZuriMED, which brings fiber-locker technology for rotator cuff repair—plugging nicely into their existing shoulder and sports medicine business.
The bigger one, though, is the strategic investment in CMR Surgical. Stryker is becoming the exclusive U.S. sales agent for CMR's Versius soft-tissue robotic platform. This is interesting because Lobo was very clear this is intentionally structured to be low-risk—they're an investor and commercial partner for now, not an outright owner.
Why not just buy the whole thing?
Lobo explained it well—he called it "derisking." Developing a soft-tissue robot from scratch is expensive and uncertain, and this lets Stryker test commercial success in the U.S. market without taking on the full financial and operational risk upfront. He compared it to their Mako acquisition history, noting CMR is actually further along in its development journey than Mako was when they bought it. The expectation—though not guaranteed—is that Stryker eventually acquires CMR outright down the road.
Meanwhile, the Vascular business is turning a corner too, after last quarter's supply disruption.
Yeah, sequential improvement there, helped partly by a one-time revenue bump from a China joint venture milestone. Underlying supply is normalizing, and they're excited about future catalysts—AVS's IVL platform launching in 2027 and important data coming from the PEERLESS II study.
Now, let's talk guidance, because this is where the market reaction probably gets interesting. Stryker revised full-year organic sales growth guidance down to 6.5%-7%, and adjusted EPS guidance to $14.80-$14.90.
Which reflects the softer hip-and-knee trends, lingering vascular supply issues, and a more conservative view on capital equipment execution. But here's the nuance—margins are actually expanding. Adjusted gross margin was up 40 basis points to 65.4%, and operating margin rose 60 basis points to 26.2%. So even with a top-line miss, profitability discipline is cushioning the blow to earnings.
And capital allocation—they bought back $1 billion in shares this quarter and got board approval for another $3 billion in buybacks, while still saying M&A remains the top priority.
Right, Preston Wells framed the buybacks as "opportunistic," not a shift away from their growth-through-acquisition strategy. They're sitting on $3.3 billion in cash and generated $3.3 billion in operating cash flow year-to-date—up 14% from last year. So the balance sheet flexibility is there.
So putting it all together—what's the takeaway for investors here?
I'd frame it as: this is a company dealing with a real, acknowledged cyclical slowdown in its most profitable segment, compounded by some self-inflicted operational noise from the SAP rollout and the cyber incident earlier in the year. But the diversification is doing its job—MedSurg, Vascular, Endoscopy, and Smart Care are all picking up slack. And management is betting on a wave of 2027 product launches—Neptune, Sonopet 3, System 10, the hip impactor, Mako Shoulder momentum—to reaccelerate growth.
It's also worth noting they're explicitly not promising a snapback in hip-and-knee demand. Lobo was candid that he doesn't have a crystal ball on timing—this could resolve quickly like past cycles, or linger.
And before we wrap, the obligatory reminder: everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Well said. So looking ahead—Stryker heads into 2027 under new CEO Spencer Stiles, with a profitable core business, a loaded product pipeline, and a genuine question mark over whether hip-and-knee demand recovers or stays depressed. It's a story worth watching closely next quarter.
Definitely one to keep on the radar as we get full-year numbers and early 2027 guidance.
That's it for this episode of Beta Finch. Thanks for listening, and we'll catch you next time as we break down the next earnings call.
See you then!